Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

血管抑制剂 阿柏西普 医学 黄斑变性 自然科学 眼科 视力 加药 贝伐单抗 外科 内科学 化疗
作者
Faye Horner,Peck Lin Lip,Bashar Mohammed,William Fusi-Rubiano,Eesha Gokhale,Bushra Mushtaq,Randhir Chavan
出处
期刊:Clinical Ophthalmology [Dove Medical Press]
卷期号:Volume 15: 1703-1713 被引量:5
标识
DOI:10.2147/opth.s305141
摘要

To compare and report the 2-year treatment outcomes from 3 different anti-VEGF treatment regimens in treating neovascular aged-related macular degeneration (nAMD): Ranibizumab pro re nata (Ranibizumab-PRN); Ranibizumab treat and extend (Ranibizumab-T&E); Aflibercept fixed first year dosing (7 injections) with treat and extend in subsequent year (Aflibercept-Fixed).All treatment-naïve nAMD patients who completed 24 months of monitoring from a single treatment center were included. Patients received the initial loading dose of three injections (4-weekly interval), followed by one of the 3 treatment regimens. Primary outcomes were changes in visual acuity (VA) and central retinal thickness (CRT). Secondary outcome was number of injections required in each year. Data analysis included last observation carried forward (LOCF) for patients with incomplete year-2 follow-up.A total of 249 eyes (230 patients) were studied: 121 Ranibizumab-PRN; 65 Ranibizumab-T&E, and 63 Aflibercept-Fixed. Baseline median VA (ETDRS letters) for Ranibizumab-PRN, Ranibizumab-T&E, and Aflibercept-Fixed was 53.9, 61.1, and 54.9 letters, achieving final VA of 54.9, 65.1, and 65.1 letters, respectively. Hence, the number of letters increased at the end of 24 months for each group was +1.0 (Ranibizumab-PRN), +4.0 (Ranibizumab-T&E), highest +10.2 in Aflibercept-Fixed group. Median number of injections over 2 years (year-1/year-2) was 5/1 for Ranibizumab-PRN, 9/6 for Ranibizumab-T&E, and 7/5 for Aflibercept-Fixed. Both Ranibizumab-T&E and Aflibercept-Fixed also shared the same reduction of median CRT (115 µm), higher than Ranibizumab-PRN (83 µm).We report VA improvement from all three different treatment regimens with both Aflibercept-Fixed and Ranibizumab-T&E regimens achieving the same higher final VA. Aflibercept-Fixed dosing may have more favorable efficacy with the highest VA gain and comparatively lower dosing frequency whereas Ranibizumab-T&E may be more efficient than Ranibizumab-PRN regimen, according to our study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汉堡包应助小猪采纳,获得10
1秒前
甜蜜的荟发布了新的文献求助10
1秒前
芜6完成签到,获得积分10
3秒前
berkelerey12138完成签到,获得积分10
3秒前
刘雪完成签到 ,获得积分10
4秒前
完美梨愁完成签到 ,获得积分10
4秒前
yyy完成签到,获得积分10
4秒前
李健的粉丝团团长应助zzzz采纳,获得10
5秒前
Dudidu完成签到,获得积分10
5秒前
一颗大树完成签到,获得积分10
6秒前
潇洒的浩然完成签到,获得积分10
7秒前
比比谁的速度快应助曾珍采纳,获得50
7秒前
9秒前
NiNi完成签到,获得积分10
10秒前
Ther完成签到,获得积分20
11秒前
傲娇白安完成签到,获得积分10
12秒前
12秒前
甜蜜的荟完成签到,获得积分20
13秒前
婷儿完成签到,获得积分10
13秒前
牛牛发布了新的文献求助10
13秒前
Hoper完成签到,获得积分10
13秒前
张曰淼完成签到,获得积分10
14秒前
共渡完成签到,获得积分10
16秒前
凉白开完成签到 ,获得积分10
17秒前
跳跃的太君完成签到,获得积分10
18秒前
小猪发布了新的文献求助10
18秒前
独特问夏完成签到,获得积分10
19秒前
19秒前
20秒前
魔幻蓉完成签到,获得积分10
20秒前
杠赛来完成签到,获得积分10
20秒前
ccy完成签到 ,获得积分10
21秒前
Ch185完成签到,获得积分10
22秒前
欣喜的复天完成签到,获得积分10
24秒前
摸鱼校尉完成签到,获得积分0
24秒前
双儿完成签到,获得积分10
24秒前
顺利毕业完成签到 ,获得积分10
24秒前
儒雅的焦完成签到 ,获得积分10
24秒前
小何完成签到 ,获得积分10
24秒前
26秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029